137 related articles for article (PubMed ID: 26875150)
21. Extrinsic blood coagulation pathway and risk factors for thrombotic events in patients with essential thrombocythemia.
Stankowska K; Gadomska G; Boinska J; Michalska M; Bartoszewska-Kubiak A; Rość D
Pol Arch Med Wewn; 2016 May; 126(5):340-6. PubMed ID: 27243342
[TBL] [Abstract][Full Text] [Related]
22. Thrombosis can occur at any phase of essential thrombocythemia with JAK2(V617F) mutation: a single institutional study in Japan.
Ohyashiki K; Ito Y; Hori K; Sato K; Makino T; Ohyashiki JH
Leukemia; 2007 Jul; 21(7):1570-1. PubMed ID: 17392820
[No Abstract] [Full Text] [Related]
23. The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis.
Qin Y; Wang X; Zhao C; Wang C; Yang Y
Int J Hematol; 2015 Aug; 102(2):170-80. PubMed ID: 25997869
[TBL] [Abstract][Full Text] [Related]
24. Leukocytosis and risk stratification assessment in essential thrombocythemia.
Carobbio A; Antonioli E; Guglielmelli P; Vannucchi AM; Delaini F; Guerini V; Finazzi G; Rambaldi A; Barbui T
J Clin Oncol; 2008 Jun; 26(16):2732-6. PubMed ID: 18443353
[TBL] [Abstract][Full Text] [Related]
25. Influence of platelet and white blood cell counts on major thrombosis - analysis from a patient registry in essential thrombocythemia.
Buxhofer-Ausch V; Steurer M; Sormann S; Schloegl E; Schimetta W; Gisslinger B; Ruckser R; Gastl G; Gisslinger H
Eur J Haematol; 2016 Dec; 97(6):511-516. PubMed ID: 27037858
[TBL] [Abstract][Full Text] [Related]
26. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
27. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) in 585 Mayo Clinic patients.
Haider M; Gangat N; Lasho T; Abou Hussein AK; Elala YC; Hanson C; Tefferi A
Am J Hematol; 2016 Jun; 91(4):390-4. PubMed ID: 26799697
[TBL] [Abstract][Full Text] [Related]
28. JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis.
De Stefano V; Rossi E; Za T; Ciminello A; Betti S; Luzzi C; Leone G; Chiusolo P
Am J Hematol; 2011 Jun; 86(6):526-8. PubMed ID: 21594892
[No Abstract] [Full Text] [Related]
29. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
30. Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea.
Alvarez-Larrán A; Martínez-Avilés L; Hernández-Boluda JC; Ferrer-Marín F; Antelo ML; Burgaleta C; Mata MI; Xicoy B; Martínez-Trillos A; Gómez-Casares MT; Durán MA; Marcote B; Ancochea A; Senín A; Angona A; Gómez M; Vicente V; Cervantes F; Bellosillo B; Besses C
Ann Hematol; 2014 Dec; 93(12):2037-43. PubMed ID: 24981691
[TBL] [Abstract][Full Text] [Related]
31. JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis.
Kurosawa H; Okuya M; Matsushita T; Kubota T; Endoh K; Kuwashima S; Hagisawa S; Sato Y; Fukushima K; Sugita K; Okada Y; Park MJ; Hayashi Y; Arisaka O
J Pediatr Hematol Oncol; 2009 Sep; 31(9):678-80. PubMed ID: 19707158
[TBL] [Abstract][Full Text] [Related]
32. Mutations and thrombosis in essential thrombocythemia.
Guglielmelli P; Gangat N; Coltro G; Lasho TL; Loscocco GG; Finke CM; Morsia E; Sordi B; Szuber N; Hanson CA; Pardanani A; Vannucchi AM; Tefferi A
Blood Cancer J; 2021 Apr; 11(4):77. PubMed ID: 33907189
[No Abstract] [Full Text] [Related]
33. High prevalence of arterial thrombosis in JAK2 mutated essential thrombocythaemia: independence of the V617F allele burden.
Larsen TS; Pallisgaard N; Møller MB; Hasselbalch HC
Hematology; 2008 Apr; 13(2):71-6. PubMed ID: 18616871
[TBL] [Abstract][Full Text] [Related]
34. Transformed essential thrombocytosis with a JAK2 V617F mutation relapsing as JAK2 mutation-negative leukaemia after allogeneic stem cell transplantation.
Au WY; Fung A; Lam KY; Lie AK; Liang R; Kwong YL
Bone Marrow Transplant; 2006 Oct; 38(8):573-4. PubMed ID: 16953212
[No Abstract] [Full Text] [Related]
35. Increased risk of heparin induced thrombocytopenia and thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation.
Castelli R; Gallipoli P; Schiavon R; Teatini T; Deliliers GL; Bergamaschini L
J Thromb Thrombolysis; 2019 Jan; 47(1):155-156. PubMed ID: 30478722
[No Abstract] [Full Text] [Related]
36. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation.
Landolfi R; Di Gennaro L; Falanga A
Leukemia; 2008 Nov; 22(11):2020-8. PubMed ID: 18800144
[TBL] [Abstract][Full Text] [Related]
37. [Essential thrombocythemia: baseline characteristics and risk factors for survival and thrombosis in a series of 214 patients].
Angona A; Alvarez-Larrán A; Bellosillo B; Martínez-Avilés L; Garcia-Pallarols F; Longarón R; Ancochea À; Besses C
Med Clin (Barc); 2015 Mar; 144(6):247-53. PubMed ID: 25192581
[TBL] [Abstract][Full Text] [Related]
38. The association of JAK2V617F mutation and leukocytosis with thrombotic events in essential thrombocythemia.
Hsiao HH; Yang MY; Liu YC; Lee CP; Yang WC; Liu TC; Chang CS; Lin SF
Exp Hematol; 2007 Nov; 35(11):1704-7. PubMed ID: 17920754
[TBL] [Abstract][Full Text] [Related]
39. JAK2 mutation: an aid in the diagnosis of occult myeloproliferative neoplasms in patients with major intraabdominal vein thrombosis and normal blood counts.
Sarid N; Eshel R; Rahamim E; Carmiel M; Kirgner I; Shpringer M; Trestman S; Marilus R; Perry C; Polliack A; Naparstek E; Herishanu Y
Isr Med Assoc J; 2013 Nov; 15(11):698-700. PubMed ID: 24511651
[TBL] [Abstract][Full Text] [Related]
40. JAK2 V617F, hemostatic polymorphisms, and clinical features as risk factors for arterial thrombotic events in essential thrombocythemia.
Moreno MJ; Lozano ML; Roldán V; Bellosillo B; García-Barberá N; Rivera J; Navarro-Núñez L; Besses C; Vicente V; Martínez C
Ann Hematol; 2008 Sep; 87(9):763-5. PubMed ID: 18365193
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]